J Pathol Transl Med.  2018 Jan;52(1):9-13. 10.4132/jptm.2017.07.26.

Programmed Death-Ligand 1 Expression and Its Correlation with Lymph Node Metastasis in Papillary Thyroid Carcinoma

Affiliations
  • 1Department of Pathology, Gyeongsang National University Changwon Hospital, Changwon, Korea. golgy@hanmail.net
  • 2Gyeongsang National University School of Medicine, Jinju, Korea.
  • 3Gyeongsang Institute of Health Science, Jinju, Korea.
  • 4Department of Pathology, Gyeongsang National University Hospital, Jinju, Korea.
  • 5Deparment of Otorhinolaryngology, Gyeongsang National University Changwon Hospital, Changwon, Korea.
  • 6Department of Surgery, Gyeongsang National University Changwon Hospital, Changwon, Korea.

Abstract

BACKGROUND
The immunotherapeutic role of programmed death-ligand 1 (PD-L1) in life expectancy in many cancers has been highlighted. However, data regarding PD-L1 expression in papillary thyroid carcinoma (PTC) are limited. In this study, we describe the PD-L1 and programmed cell death protein 1 (PD-1) expressions in PTC and analyze their correlation with lymph node (LN) metastasis.
METHODS
Clinicopathological data were obtained from 116 patients with PTC who were treated in Gyeongsang National University Hospital, Jinju, Korea in 2009. Tissue microarray blocks were made using representative paraffin blocks of classical PTCs excluding follicular variants. Two pathologists graded the proportion and intensity of PD-L1 and PD-1 expression in both tumor and inflammatory cells. According to their proportions, positive PTC cells were scored as negative (0%), grade 1 (1%-50%), and grade 2 (51%-100%). Similarly, positive inflammatory cells were graded as negative (0%), grade 1 (1%-10%), and grade 2 (11%-20%). The intensity of each protein expression was simplified as positive or negative.
RESULTS
A statistically significant correlation exists between the proportions of PD-1 and PD-L1 expression both in papillary carcinoma (p=.001) and peritumoral lymphoid cells in the thyroid (p<.001). In addition, the proportion of PD-L1 expression in PTC cells was closely related to metastatic LNs (p=.036).
CONCLUSIONS
PD-L1 is a valuable predictive marker for LN metastasis in PTC. Immunomodulating therapies that inhibit PD-L1 might be an option for patients with LN metastasis.

Keyword

Programmed death-ligand 1; Carcinoma, papillary; Thyroid; Lymph nodes; Neoplasm metastasis
Full Text Links
  • JPTM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr